Results 221 to 230 of about 20,052 (248)

Semaglutide ameliorates coronary microembolization-induced injury by suppressing apoptosis and inflammation via the HMGB1/RAGE/NF-κB p65 pathway. [PDF]

J Geriatr Cardiol
Yang HF, Li HQ, Wang Q, Wang XT, Li L.
europepmc   +1 more source

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

Obesity Reviews, EarlyView.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira, ZhiDi Deng, Manfred J. Muller, Giovanna G. L. Bergamasco, Sarah Cawsey, Melania Manco, Steven B. Heymsfield, Carla M. Prado, Andrea M. Haqq   +8 more
wiley   +1 more source

Retrospective comparison of the clinical effects of oral semaglutide and SGLT2 inhibitors treatment in patients with type 2 diabetes. [PDF]

J Diabetes Investig
Omori Y, Usui R, Yamazaki Y, Kuwata H, Hamamoto Y, Yamada Y, Seino Y.   +6 more
europepmc   +1 more source

A Systematic Review and Meta‐Analysis of Randomized Controlled Trials of Behavioral Interventions for the Management of Overweight and Obesity in Children That Are Delivered or Referred to by Health Providers in Primary Care

Obesity Reviews, EarlyView.
ABSTRACT Introduction Reducing childhood overweight and obesity prevalence is a global public health priority. This systematic review and meta‐analysis evaluated the effectiveness of behavioral weight management interventions delivered or referred to by health care providers in primary care settings.
Henrietta E. Graham, Claire D. Madigan, Kajal Gokal, Jessica F. Large, James Sanders, Chris J. McLeod, Natalie Pearson, Amanda J. Daley   +7 more
wiley   +1 more source

Muscle Dysfunction and Bone Loss in a Woman With Cystic Fibrosis and Obesity Treated With Glucagon-Like Peptide 1 Agonist: A Case Report. [PDF]

Respirol Case Rep
Kumar S, Cobb R, Matson A, Lee J, Henderson D.   +4 more
europepmc   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT Introduction Increased risk of suicidality has been reported in association with glucagon‐like peptide receptor agonist (GLP‐1 RA) prescription. Herein, we conducted a comprehensive review evaluating reports of GLP‐1 RA prescription and suicidality.
Hezekiah C. T. Au, Yang Jing Zheng, Gia Han Le, Sabrina Wong, Kayla M. Teopiz, Angela T. H. Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur, Hayun Choi, Roger S. McIntyre   +9 more
wiley   +1 more source

Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study. [PDF]

J Endocrinol Invest
le Roux CW, Done N, Brnabic AJM, Zion A, Lipkovich I, Kadziola Z, Dunn JP, Desai U, Kirson N, Dimitriadis GK, Kan H.   +10 more
europepmc   +1 more source

Engineering Marker‐Free Lettuce Chloroplast Genome to Express Functional Glucagon‐Like Peptide‐1 Receptor Agonists Exenatide and Lixisenatide

Plant Biotechnology Journal, EarlyView.
Engineering of marker‐free lettuce chloroplast genome to express CTB‐Exenatide and CTB‐Lixisenatide for oral delivery. Upper panel: Chemically synthesised exenatide or lixisenatide require expensive production, purification, refrigeration and invasive delivery methods.
Rahul Singh, Henry Daniell
wiley   +1 more source

Real-world clinical and budget impact of semaglutide in type 2 diabetes mellitus in tertiary hospital in Saudi Arabia. [PDF]

Front Clin Diabetes Healthc
Al-Abdulkarim HA, Alqahtani NS, Al-Shraim M, Almohammed OA.   +3 more
europepmc   +1 more source